Literature DB >> 7974205

Effects of prenatal cocaine exposure upon postnatal development of neostriatal dopaminergic function.

C A Leslie1, M W Robertson, A B Jung, J Liebermann, J P Bennett.   

Abstract

Pregnant rats were injected twice daily with 20 mg/kg cocaine (or saline) from gestational day 10 to parturition. Brains from offspring were examined with quantitative receptor autoradiography [D1 receptor (D1R), D2 receptor (D2R) and dopamine transporter (DAT)] and quantitative in situ hybridization [D1R mRNA, D2R mRNA, preproenkephalin (PPE) mRNA] for markers of neostriatal dopaminergic function. Prenatal cocaine exposure did not alter postnatal development of striatal D1R sites, but D1R mRNA levels were reduced by a third at days 14 and 35. D2R sites were increased over control in lateral striatum by day 6, and remained elevated through postnatal day 35. Total D2R mRNA was increased over control in both medial and lateral striatum at 7 and 14 days but was equal to control at 35 days. Prenatal cocaine exposure increased DAT density at postnatal days 1 through 5, but reduced it at days 14 and 35; PPE mRNA expression was reduced at days 7, 14 and 35. Many of these results are similar to those found in experimental animals and humans following cocaine withdrawal.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7974205     DOI: 10.1002/syn.890170311

Source DB:  PubMed          Journal:  Synapse        ISSN: 0887-4476            Impact factor:   2.562


  10 in total

1.  Gender differences in prodynorphin but not proenkephalin mRNA expression in the striatum of adolescent rats exposed to prenatal cocaine.

Authors:  Annelyn Torres-Reveron; Yasmin L Hurd; Diana L Dow-Edwards
Journal:  Neurosci Lett       Date:  2007-05-05       Impact factor: 3.046

2.  Prenatal cocaine exposure increases sensitivity to the attentional effects of the dopamine D1 agonist SKF81297.

Authors:  L E Bayer; A Brown; C F Mactutus; R M Booze; B J Strupp
Journal:  J Neurosci       Date:  2000-12-01       Impact factor: 6.167

3.  Prenatal amphetamine exposure effects on dopaminergic receptors and transporter in postnatal rats.

Authors:  Gonzalo Flores; María de Jesús Gómez-Villalobos; Leonardo Rodríguez-Sosa
Journal:  Neurochem Res       Date:  2011-05-25       Impact factor: 3.996

Review 4.  The role of mesocorticolimbic dopamine in regulating interactions between drugs of abuse and social behavior.

Authors:  Kimberly A Young; Kyle L Gobrogge; Zuoxin Wang
Journal:  Neurosci Biobehav Rev       Date:  2010-06-23       Impact factor: 8.989

5.  Cocaine upregulates the dopamine transporter in fetal rhesus monkey brain.

Authors:  Y Fang; O K Ronnekleiv
Journal:  J Neurosci       Date:  1999-10-15       Impact factor: 6.167

6.  Effects of prenatal exposure to cocaine on the developing brain: anatomical, chemical, physiological and behavioral consequences.

Authors:  J A Harvey; A G Romano; M Gabriel; K J Simansky; W Du; V J Aloyo; E Friedman
Journal:  Neurotox Res       Date:  2001-01       Impact factor: 3.911

Review 7.  Cocaine-induced neurodevelopmental deficits and underlying mechanisms.

Authors:  Melissa M Martin; Devon L Graham; Deirdre M McCarthy; Pradeep G Bhide; Gregg D Stanwood
Journal:  Birth Defects Res C Embryo Today       Date:  2016-06

Review 8.  A meta-analysis of animal studies on disruption of spatial navigation by prenatal cocaine exposure.

Authors:  George H Trksak; Stephen J Glatt; Farzad Mortazavi; Denise Jackson
Journal:  Neurotoxicol Teratol       Date:  2007-06-30       Impact factor: 3.763

9.  Altered baseline and amphetamine-mediated behavioral profiles in dopamine transporter Cre (DAT-Ires-Cre) mice compared to tyrosine hydroxylase Cre (TH-Cre) mice.

Authors:  Muhammad O Chohan; Sari Esses; Julia Haft; Susanne E Ahmari; Jeremy Veenstra-VanderWeele
Journal:  Psychopharmacology (Berl)       Date:  2020-08-10       Impact factor: 4.415

10.  Classic Studies on the Interaction of Cocaine and the Dopamine Transporter.

Authors:  Vivek Verma
Journal:  Clin Psychopharmacol Neurosci       Date:  2015-12-31       Impact factor: 2.582

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.